Human Lung Organoids—A Novel Experimental and Precision Medicine Approach

Author:

Kühl Laura1,Graichen Pauline1,von Daacke Nele1,Mende Anne1,Wygrecka Malgorzata234ORCID,Potaczek Daniel P.125ORCID,Miethe Sarah1,Garn Holger1ORCID

Affiliation:

1. Translational Inflammation Research Division & Core Facility for Single Cell Multiomics, Medical Faculty, Philipps University of Marburg, Member of the German Center for Lung Research (DZL) and the Universities of Giessen and Marburg Lung Center, 35043 Marburg, Germany

2. Center for Infection and Genomics of the Lung (CIGL), Universities of Giessen and Marburg Lung Center (UGMLC), 35392 Giessen, Germany

3. Institute of Lung Health, German Center for Lung Research (DZL), 35392 Giessen, Germany

4. CSL Behring Innovation GmbH, 35041 Marburg, Germany

5. Bioscientia MVZ Labor Mittelhessen GmbH, 35394 Giessen, Germany

Abstract

The global burden of respiratory diseases is very high and still on the rise, prompting the need for accurate models for basic and translational research. Several model systems are currently available ranging from simple airway cell cultures to complex tissue-engineered lungs. In recent years, human lung organoids have been established as highly transferrable three-dimensional in vitro model systems for lung research. For acute infectious and chronic inflammatory diseases as well as lung cancer, human lung organoids have opened possibilities for precise in vitro research and a deeper understanding of mechanisms underlying lung injury and regeneration. Human lung organoids from induced pluripotent stem cells or from adult stem cells of patients’ samples introduce tools for understanding developmental processes and personalized medicine approaches. When further state-of-the-art technologies and protocols come into use, the full potential of human lung organoids can be harnessed. High-throughput assays in drug development, gene therapy, and organoid transplantation are current applications of organoids in translational research. In this review, we emphasize novel approaches in translational and personalized medicine in lung research focusing on the use of human lung organoids.

Funder

German “Bundesinstitut für Risikoforschung”

Publisher

MDPI AG

Subject

General Medicine

Reference135 articles.

1. The global burden of respiratory disease;Ferkol;Ann. Am. Thorac. Soc.,2014

2. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: Systematic analysis for the Global Burden of Disease Study 2017;Li;BMJ,2020

3. GBD Chronic Respiratory Disease Collaborators (2020). Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir. Med., 8, 585–596.

4. WHO (2023, July 28). Estimated Age-Standardized Mortality Rates (World) in 2020, World, Both Sexes, All Ages (excl. NMSC). Available online: https://gco.iarc.fr/today/online-analysis-multi-bars.

5. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016-40 for 195 countries and territories;Foreman;Lancet,2018

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Mesenchymal Stromal Cell Therapy for Thoracic Surgeons: An Update;Journal of Personalized Medicine;2023-11-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3